Immunovant, Inc.IMVTNASDAQ
Loading
Free Cash Flow Growth Under PressureDecelerating
Percentile Rank73
5Y CAGR+11.3%
Year-over-Year Change
Year-over-year free cash flow growth rate
5Y CAGR
+11.3%/yr
Long-term compound
Percentile
P73
Within normal range
vs 5Y Ago
1.7x
Solid growth
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 9.94% |
| Q3 2025 | 12.69% |
| Q2 2025 | -5.93% |
| Q1 2025 | -10.21% |
| Q4 2024 | -13.20% |
| Q3 2024 | -16.32% |
| Q2 2024 | -27.62% |
| Q1 2024 | -26.72% |
| Q4 2023 | 21.41% |
| Q3 2023 | -26.74% |
| Q2 2023 | 15.06% |
| Q1 2023 | -20.06% |
| Q4 2022 | -129.97% |
| Q3 2022 | 69.30% |
| Q2 2022 | -99.13% |
| Q1 2022 | -3.46% |
| Q4 2021 | -59.12% |
| Q3 2021 | 5.37% |
| Q2 2021 | 6.02% |
| Q1 2021 | 1.11% |
| Q4 2020 | 5.83% |
| Q3 2020 | -75.20% |
| Q2 2020 | 39.96% |
| Q1 2020 | -520324.28% |
| Q4 2019 | 98.53% |
| Q3 2019 | -30.93% |
| Q2 2019 | -51052.63% |
| Q1 2019 | 93.95% |
| Q4 2018 | -115.91% |
| Q3 2018 | 31.96% |
| Q2 2018 | 0.00% |